Showing results (181-190 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|August 14, 2018
Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic reviewMatthijs van der Meulen, Linda Dirven, Esther J J Habets, et al.
The Lancet. Oncology|August 14, 2018
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour GroupStefan Rutkowski, Piergiorgio Modena, Daniel Williamson, et al.
The Lancet. Oncology|July 2, 2018
Relapse of Wilms' tumour and detection methods: a retrospective analysis of the 2001 Renal Tumour Study Group-International Society of Paediatric Oncology Wilms' tumour protocol databaseJesper Brok, Marta Lopez-Yurda, Harm V Tinteren, et al.
The Lancet. Oncology|May 21, 2018
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysisFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
The Lancet. Oncology|July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trialAmit M Oza, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
The Lancet. Oncology|September 24, 2021
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional surveyAdam Fundytus, Manju Sengar, Dorothy Lombe, et al.
The Lancet. Oncology|May 5, 2022
Assessment of the 2020 NICE criteria for preoperative radiotherapy in patients with rectal cancer treated by surgery alone in comparison with proven MRI prognostic factors: a retrospective cohort studyAmy C Lord, Alison Corr, Anuradha Chandramohan, et al.
The Lancet. Oncology|July 10, 2022
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A Reiss, Rosemarie Mick, Ursina Teitelbaum, et al.
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Pageof 336